Investigator

Marketa Janatova

Clinical bioanalyst for medical genetics · General University Hospital in Prague, The Institute of Medical Biochemistry and Laboratory Diagnostics

Research Interests

MJMarketa Janatova
Papers(2)
Population‐specific v…Early-Onset Ovarian C…
Collaborators(5)
Zdenek KleiblPetra KleiblovaCorinna ErnstJana SoukupovaKlara Horackova
Institutions(2)
Charles UniversityMedizinische Hochschu…

Papers

Population‐specific validation and comparison of the performance of 77‐ and 313‐variant polygenic risk scores for breast cancer risk prediction

AbstractBackgroundThe polygenic risk score (PRS) allows the quantification of the polygenic effect of many low‐penetrance alleles on the risk of breast cancer (BC). This study aimed to evaluate the performance of two sets comprising 77 or 313 low‐penetrance loci (PRS77 and PRS313) in patients with BC in the Czech population.MethodsIn a retrospective case‐control study, variants were genotyped from both the PRS77 and PRS313 sets in 1329 patients with BC and 1324 noncancer controls, all women without germline pathogenic variants in BC predisposition genes. Odds ratios (ORs) were calculated according to the categorical PRS in individual deciles. Weighted Cox regression analysis was used to estimate the hazard ratio (HR) per standard deviation (SD) increase in PRS.ResultsThe distributions of standardized PRSs in patients and controls were significantly different (p < 2.2 × 10−16) with both sets. PRS313 outperformed PRS77 in categorical and continuous PRS analyses. For patients in the highest 2.5% of PRS313, the risk reached an OR of 3.05 (95% CI, 1.66–5.89; p = 1.76 × 10−4). The continuous risk was estimated as an HRper SD of 1.64 (95% CI, 1.49–1.81; p < 2.0 × 10−16), which resulted in an absolute risk of 21.03% at age 80 years for individuals in the 95th percentile of PRS313. Discordant categorization into PRS deciles was observed in 248 individuals (9.3%).ConclusionsBoth PRS77 and PRS313 are able to stratify individuals according to their BC risk in the Czech population. PRS313 shows better discriminatory ability. The results support the potential clinical utility of using PRS313 in individualized BC risk prediction.

84Works
2Papers
5Collaborators
Genetic Predisposition to DiseaseBreast NeoplasmsOvarian NeoplasmsCarcinoma, Ovarian EpithelialTumor Suppressor Proteins

Positions

2022–

Clinical bioanalyst for medical genetics

General University Hospital in Prague · The Institute of Medical Biochemistry and Laboratory Diagnostics

2022–

Assistant Professor and researcher

Univerzita Karlova 1. lékařská fakulta · Institute of Medical Biochemistry and Laboratory Diagnostics

2012–

Clinical bioanalyst for medical genetics

General University Hospital in Prague · The Institute of Biology and Medical Genetics

2001–

Assistant Professor and researcher

Univerzita Karlova 1. lékařská fakulta · Institute of Biochemistry and Medical Oncology